A multicenter randomized controlled clinical trial confirms that both chemical-first and electrical-first approaches are effective strategies for acute atrial fibrillation; however, an ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Demonstrating one potential application of the technology, an automated algorithm tied to the KardiaBand wearable ECG (AliveCor) performed “reasonably well” at detecting A-fib in patients scheduled ...

A newly-designed wristband and corresponding app that works with a smartwatch can accurately display the heart's electrical activity and notify people with atrial fibrillation (AFib) if their heart is ...

ROME -- Edoxaban (Savaysa) appears at least as safe as the standard warfarin (Coumadin)/enoxaparin (Lovenox) strategy for use in bridging anticoagulation around cardioversion for recent onset atrial ...

Pharmacological- and electrical-first cardioversion worked similarly well for treating acute atrial fibrillation (Afib) in the emergency department, according to the Canadian RAFF2 trial. The 204 ...

Milestone Pharma begins pivotal phase 3 trial of etripamil nasal spray for self-administered treatment of AFib-RVR: Montreal Monday, August 24, 2026, 14:00 Hrs [IST] Milestone Pha ...

The DECAF randomized trial found that adults with persistent atrial fibrillation or atrial flutter assigned to drink at least ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...